Review metabolomics: A new approach to drug delivery in perinatology

Current Medicinal Chemistry

Volumn 19, Issue 27, 2012, Pages 4654-4661

  Atzori, L ^a   Griffin, J L ^b,c   Noto, A ^a   Fanos, V ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Ductus arteriosus; Indometacin; Metabolomics; NSAIDs; Perinatal pharmacology; Pharmacology; Preterm newborn; Prophylaxis

Indexed keywords

BIOLOGICAL MARKER; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT;

BREAST MILK; CHEMICAL STRUCTURE; CHEMOMETRICS; DATA MINING; GENOMICS; HUMAN; INDEPENDENT VARIABLE; METABOLITE; METABOLOMICS; PATENT DUCTUS ARTERIOSUS; PERINATAL CARE; PERINATAL PERIOD; PHENOTYPE; PREDICTION; PREMATURITY; RESPIRATORY DISTRESS SYNDROME; REVIEW; SYSTEMS BIOLOGY; THERAPY EFFECT; TREATMENT RESPONSE; CHEMISTRY; INTRAUTERINE GROWTH RETARDATION; METABOLISM; METABOLOME; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PATHOLOGY; PERINATOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; METABOLOME; METABOLOMICS; MILK, HUMAN; PERINATOLOGY; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 84875263481     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803306448     Document Type: Review

References (70)

1. Mroziewicz, M.; Tyndale, R. F. Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addiction science & clinical practice 2010, 5, 17-29.
2. Rodin, A. S.; Gogoshin, G.; Boerwinkle, E. Systems biology data analysis methodology in pharmacogenomics. Pharmacogenomics 2011, 12, 1349-60.
3. Hocquette, J. F. Where are we in genomics? Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 2005, 56 Suppl 3, 37-70.
4. Becker, M. L.; Leeder, J. S. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics 2010, 11, 1591-602.
5. Nicholson, J. K.; Lindon, J. C. Systems biology: Metabonomics. Nature 2008, 455, 1054-6.
6. Want, E. J.; Wilson, I. D.; Gika, H.; Theodoridis, G.; Plumb, R. S.; Shockcor, J.; Holmes, E.; Nicholson, J. K. Global metabolic profiling procedures for urine using UPLC-MS. Nature protocols 2010, 5, 1005-18.
7. Nicholson, G.; Rantalainen, M.; Maher, A. D.; Li, J. V.; Malmodin, D.; Ahmadi, K. R.; Faber, J. H.; Hallgrímsdóttir, I. B.; Barrett, A.; Toft, H.; Krestyaninova, M.; Viksna, J.; Neogi, S. G.; Dumas, M.-E.; Sarkans, U.; Silverman, B. W.; Donnelly, P.; Nicholson, J. K.; Allen, M.; Zondervan, K. T.; Lindon, J. C.; Spector, T. D.; McCarthy, M. I.; Holmes, E.; Baunsgaard, D.; Holmes, C. C. Human metabolic profiles are stably controlled by genetic and environmental variation. Molecular Systems Biology 2011, 7, 525.
8. Principles of pharmacology: the pathophysiologic basis of drug therapy; Lippincott Williams & Wilkins, 2008; p. 985.
9. Pinto, N.; Dolan, M. E. Clinically relevant genetic variations in drug metabolizing enzymes. Current drug metabolism 2011, 12, 487-97.
10. Smits, A.; Allegaert, K. Perinatal pharmacology: applications for neonatal neurology. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 2011, 15, 478-86.
11. Roberts, R.; Rodriguez, W.; Murphy, D.; Crescenzi, T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA: the journal of the American Medical Association 2003, 290, 905-11.
12. Basic and Clinical Pharmacology, 11th Edition; McGraw-Hill Medical; 11 edition, 2009; p. 1232.
13. Pacifici, G. M. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. European journal of clinical pharmacology 2009, 65, 419-27.
14. Yeung, M. Y. Postnatal growth, neurodevelopment and altered adiposity after preterm birth-from a clinical nutrition perspective. Acta paediatrica [Oslo, Norway: 1992) 2006, 95, 909-17.
15. Lafeber, H. N. Nutritional assessment and measurement of body composition in preterm infants. Clinics in perinatology 1999, 26, 997-1005.
16. Bell, E. F. Diet and body composition of preterm infants. Acta paediatrica Supplement 1994, 405, 25-8.
17. Piñeiro-Carrero, V. M.; Piñeiro, E. O. Liver. Pediatrics 2004, 113, 1097-106.
18. Cuzzolin, L.; Fanos, V.; Pinna, B.; di Marzio, M.; Perin, M.; Tramontozzi, P.; Tonetto, P.; Cataldi, L. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatric nephrology 2006, 21, 931-8.
19. Mussap, M.; Cataldi, L.; Plebani, M.; Fanos, V. Laboratory investigation for the early diagnosis and monitoring of neonatal urinary tract infections: the present situation and future perspectives. Journal of chemotherapy 2006, 18 Spec no,9-13.
20. Mussap, M.; Fanos, V. Neonatal nephrology and laboratory medicine: an effective interdisciplinary model to improve the outcome in neonatal intensive care unit. Journal Maternal Fetal Neonatal Medicine 2011, 24 Suppl 2, 1-2.
21. Gehlenborg, N.; O'Donoghue, S. I.; Baliga, N. S.; Goesmann, A.; Hibbs, M. A.; Kitano, H.; Kohlbacher, O.; Neuweger, H.; Schneider, R.; Tenenbaum, D.; Gavin, A.-C. Visualization of omics data for systems biology. Nature methods 2010, 7, S56-68.
22. Gomase, V. S.; Changbhale, S. S.; Patil, S. A.; Kale, K. V. Metabolomics. Current drug metabolism 2008, 9, 89-98.
23. Kell, D. B. Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug discovery today 2006, 11, 1085-92.
24. Nicholson, J. K.; Connelly, J.; Lindon, J. C.; Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nature reviews. Drug discovery 2002, 1, 153-61.
25. Ellis, D. I.; Dunn, W. B.; Griffin, J. L.; Allwood, J. W.; Goodacre, R. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007, 8, 1243-66.
26. Fiehn, O. Metabolomics-the link between genotypes and phenotypes. Plant molecular biology 2002, 48, 155-71.
27. Dunn, W. B.; Broadhurst, D. I.; Atherton, H. J.; Goodacre, R.; Griffin, J. L. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society reviews 2011, 40, 387-426.
28. Atzori, L.; Antonucci, R.; Barberini, L.; Griffin, J. L.; Fanos, V. Metabolomics: a new tool for the neonatologist. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2009, 22 Suppl 3, 50-3.
29. Atzei, A.; Atzori, L.; Moretti, C.; Barberini, L.; Noto, A.; Ottonello, G.; Pusceddu, E.; Fanos, V. Metabolomics in paediatric respiratory diseases and bronchiolitis. J. Matern. Fetal. Neonatol., 2011, 24 Suppl 2, 59-62.
30. Atzori, L.; Xanthos, T.; Barberini, L.; Antonucci, R.; Murgia, F.; Lussu, M.; Aroni, F.; Varsami, M.; Papalois, A.; Lai, A.; D'Aloja, E.; Iacovidou, N.; Fanos, V. A metabolomic approach in an experimental model of hypoxiareoxygenation in newborn piglets: urine predicts outcome. Journal Maternal Fetal Neonatal Medicine 2010, 23 Suppl 3, 134-7.
31. Fabiano, A.; Gazzolo, D.; Zimmermann, L. J. I.; Gavilanes, A. W. D.; Paolillo, P.; Fanos, V.; Caboni, P.; Barberini, L.; Noto, A.; Atzori, L. Metabolomic analysis of bronchoalveolar lavage fluid in preterm infants complicated by respiratory distress syndrome: preliminary results. Journal Maternal Fetal Neonatal Medicine 2011, 24 Suppl 2, 55-8.
32. Atzori, L.; Antonucci, R.; Barberini, L.; Locci, E.; Marincola, F. C.; Scano, P.; Cortesi, P.; Agostiniani, R.; Defraia, R.; Weljie, A.; Gazzolo, D.; Lai, A.; Fanos, V. 1H NMR-based metabolomic analysis of urine from preterm and term neonates. Frontiers in bioscience (Elite edition) 2011, 3, 1005-12.
33. Coen, M.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chemical research in toxicology 2008, 21, 9-27.
34. Fell, J. M.; Thakkar, H.; Newman, D. J.; Price, C. P. Measurement of albumin and low molecular weight proteins in the urine of newborn infants using a cotton wool ball collection method. Acta paediatrica 1997, 86, 518-22.
35. Griffin, J.L.; Atherton, H.; Shockcor, J.; Atzori, L. Metabolomics as a tool for the cardiologist. Nature Rev Cardiology. 2011; 8: 630-43.
36. Malet-Martino, M.; Holzgrabe, U. NMR techniques in biomedical and pharmaceutical analysis. Journal of pharmaceutical and biomedical analysis 2011, 55, 1-15.
37. Lindon, J. C.; Nicholson, J. K. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annual review of analytical chemistry 2008, 1, 45-69.
38. Want, E.; Masson, P. Processing and analysis of GC/LC-MS-based metabolomics data. Methods in molecular biology 2011, 708, 277-98.
39. Chemometrics for pattern recognition (Google eBook); John Wiley and Sons, 2009; p. 504.
40. Madsen, R.; Lundstedt, T.; Trygg, J. Chemometrics in metabolomics-a review in human disease diagnosis. Analytica chimica acta 2010, 659, 23-33.
41. Johnson, C. H.; Patterson, A. D.; Idle, J. R.; Gonzalez, F. J. Xenobiotic metabolomics: major impact on the metabolome. Annual review of pharmacology and toxicology 2012, 52, 37-56.
42. Lindon, J. C.; Holmes, E.; Nicholson, J. K. Metabonomics techniques and applications to pharmaceutical research & development. Pharmaceutical research 2006, 23, 1075-88.
43. Clayton, T. A.; Lindon, J. C.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton, G.; Provost, J.-P.; Le Net, J.-L.; Baker, D.; Walley, R. J.; Everett, J. R.; Nicholson, J. K. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006, 440, 1073-7.
44. Fukuhara, K.; Ohno, A.; Ando, Y.; Yamoto, T.; Okuda, H. A 1H NMR-based metabolomics approach for mechanistic insight into acetaminophen-induced hepatotoxicity. Drug metabolism and pharmacokinetics 2011, 26, 399-406.
45. Wang, X.; Wang, H.; Zhang, A.; Lu, X.; Sun, H.; Dong, H.; Wang, P. Metabolomics Study on the Toxicity of Aconite Root and Its Processed Products Using Ultraperformance Liquid-Chromatography/Electrospray-Ionization Synapt High-Definition Mass Spectrometry Coupled with Pattern Recognition Approach and Ingenuity Pathways. Journal of proteome research 2011.
46. Lodi, A.; Ronen, S. M. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PloS one 2011, 6, e26155.
47. Kaddurah-Daouk, R.; Kristal, B. S.; Weinshilboum, R. M. Metabolomics: a global biochemical approach to drug response and disease. Annual review of pharmacology and toxicology 2008, 48, 653-83.
48. Fanos, V.; Benini, D.; Verlato, G.; Errico, G.; Cuzzolin, L. Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundamental & clinical pharmacology 2005, 19, 187-93.
49. Antonucci, R.; Cuzzolin, L.; Arceri, A.; Dessì, A.; Fanos, V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. European journal of clinical pharmacology 2009, 65, 223-30.
50. Longini, M.; Perrone, S.; Vezzosi, P.; Proietti, F.; Marzocchi, B.; Buonocore, G.; Fanos, V.; Antonucci, R.; Brunoldi, E. Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure. Pediatric nephrology (Berlin, Germany) 2011, 26, 105-9.
51. Noori, S.; Patel, D.; Friedlich, P.; Siassi, B.; Seri, I.; Ramanathan, R. Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants. Journal of perinatology: official journal of the California Perinatal Association 2009, 29, 553-7.
52. Evans, N. Patent ductus arteriosus and effects of low oxygen saturation limits. Journal of perinatology: official journal of the California Perinatal Association 2009, 29, 529-30.
53. El Hajjar, M.; Vaksmann, G.; Rakza, T.; Kongolo, G.; Storme, L. Severity of the ductal shunt: a comparison of different markers. Archives of disease in childhood. Fetal and neonatal edition 2005, 90, F419-22.
54. Fanos, V.; Marcialis, M. A.; Bassareo, P. P.; Antonucci, R.; Zaffanello, M.; Dessì, A.; Iacovidou, N. Renal safety of Non Steroidal Anti Inflammatory Drugs (NSAIDs) in the pharmacologic treatment of patent ductus arteriosus. Journal Maternal Fetal Neonatal Medicine 2011, 24 Suppl 1, 50-2.
55. Fanos, V.; Pusceddu, M.; Dessì, A.; Marcialis, M. A. Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns? Clinics (São Paulo, Brazil) 2011, 66, 2141-9.
56. Antonucci, R.; Bassareo, P.; Zaffanello, M.; Pusceddu, M.; Fanos, V. Patent ductus arteriosus in the preterm infant: new insights into pathogenesis and clinical management. Journal Maternal Fetal Neonatal Medicine 2010, 23 Suppl 3, 34-7.
57. Bassareo, P. P.; Fanos, V.; Crisafulli, A.; Mura, R.; Mercuro, G. Cardiovascular phenotype in extremely low birth weight infants: long-term consequences. Journal Maternal Fetal Neonatal Medicine 2011, 24 Suppl 2, 4-6.
58. Intrauterine growth restriction. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. 2001, 72, 85-96.
59. Diderholm, B. Perinatal energy metabolism with reference to IUGR & SGA: studies in pregnant women & newborn infants. The Indian journal of medical research 2009, 130, 612-7.
60. Rosso, P.; Winick, M. Intrauterine growth retardation. A new systematic approach based on the clinical and biochemical characteristics of this condition. Journal of perinatal medicine 1974, 2, 147-60.
61. Pallotto, E. K.; Kilbride, H. W. Perinatal outcome and later implications of intrauterine growth restriction. Clinical obstetrics and gynecology 2006, 49, 257-69.
62. Béringue, F.; Blondeau, B.; Castellotti, M. C.; Bréant, B.; Czernichow, P.; Polak, M. Endocrine pancreas development in growth-retarded human fetuses. Diabetes 2002, 51, 385-91.
63. Dessì, A.; Atzori, L.; Noto, A.; Visser, G. H. A.; Gazzolo, D.; Zanardo, V.; Barberini, L.; Puddu, M.; Ottonello, G.; Atzei, A.; De Magistris, A.; Lussu, M.; Murgia, F.; Fanos, V. Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. Journal Maternal Fetal Neonatal Medicine 2011, 24 Suppl 2, 35-9.
64. Bancalari, E.; Claure, N. Definitions and diagnostic criteria for bronchopulmonary dysplasia. Seminars in perinatology 2006, 30, 164-70.
65. Gien, J.; Kinsella, J. P. Pathogenesis and treatment of bronchopulmonary dysplasia. Current opinion in pediatrics 2011, 23, 305-13.
66. Been, J. V.; Debeer, A.; van Iwaarden, J. F.; Kloosterboer, N.; Passos, V. L.; Naulaers, G.; Zimmermann, L. J. Early alterations of growth factor patterns in bronchoalveolar lavage fluid from preterm infants developing bronchopulmonary dysplasia. Pediatric research 2010, 67, 83-9.
67. Hasan, J.; Beharry, K. D.; Valencia, A. M.; Strauss, A.; Modanlou, H. D. Soluble vascular endothelial growth factor receptor 1 in tracheal aspirate fluid of preterm neonates at birth may be predictive of bronchopulmonary dysplasia/chronic lung disease. Pediatrics 2009, 123, 1541-7.
68. Flaminia Cesare Marincola F, Reali A, Barberini L, et al. NMR metabolic target analysis of the human breast milk aqueous extract. Journal Maternal Fetal Neonatal Medicine 2011
69. Ammenti, A.; Cataldi, L.; Chimenz, R.; Fanos, V.; La Manna, A.; Marra, G.; Materassi, M.; Pecile, P.; Pennesi, M.; Pisanello, L.; Sica, F.; Toffolo, A.; Montini, G. Febrile urinary tract infections in young children: recommendations for the diagnosis, treatment and follow-up. Acta paediatrica 2011.
70. Fanos et al. Pharma-Metabolomics in Neonatology: is it a Dream or a Fact? Current pharmaceutical design, 2012, 18, 2996-3006.